Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704730 · ClinicalTrials.gov registry record · Phase 3
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
A Phase 3 study of Thyroid Cancer, sponsored by Exelixis.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT00704730: Completed Phase 3 study of Thyroid Cancer, sponsored by Exelixis.
NCT00704730 is a Phase 3 study of Thyroid Cancer that has completed, run by Exelixis. The registered enrollment target is 330 participants, above the 275-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00704730, a Phase 3 study of Thyroid Cancer, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive XL184 or placebo in a 2:1 ratio. XL184 is an investigational drug that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration. The Clinical Steering Committee for this study, comprised of study doctors who specialize in medullary thyroid cancer, has provided guidance regarding the design of the study. The committee includes: Douglas Ball, MD, Barry Nelkin, PhD, Martin Schlumberger, MD and Steven Sherman, MD.
Primary Outcome
The duration of Progression-Free Survival (PFS) using progression events as determined by Independent Review Committee (IRC) per mRECIST, or death due to any cause. The analysis was conducted after at least 315 subjects were randomized and at least 138 events were observed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG XL184
Study Locations (20)
California
- - Burbank
- UCLA - Los Angeles
- Stanford Cancer Center - Stanford
Missouri
- Capitol Comprehensive Cancer Care Clinic and Research Institute - Jefferson City
- Washington University School of Medicine - St Louis
Alabama
- University of Alabama at Birmingham, Comprehensive Cancer Center - Birmingham
Arizona
- TGEN Clinical Research Service at Scottsdale Healthcare - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Cancer Center - Aurora
Connecticut
- Yale University, School of Medicine - New Haven
District of Columbia
- Washington Cancer Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2008-06 |
| Est. Completion | 2020-09 |
| Phase | Phase 3 |
What the finished NCT00704730 record still lists
NCT00704730 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 275-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00704730 names 20 study sites across 17 states, led by California, Missouri, Alabama.
Frequently Asked Questions
What is clinical trial NCT00704730 about?
NCT00704730 is a clinical study titled "Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer". The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive XL184 or placebo in ...
What is the current status of trial NCT00704730?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2008-06. Estimated completion is 2020-09.
What conditions does trial NCT00704730 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT00704730?
The interventions under investigation include: Placebo (DRUG), XL184 (DRUG).
Who is sponsoring clinical trial NCT00704730?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00704730 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00704730's enrollment target sits among peer trials
330 8th of 46 higher than 39 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
RECRUITING · Phase 3
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
COMPLETED · Phase 3
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia